瑞戈非尼联合纳武利尤单抗治疗错配修复功能完整晚期难治性结直肠癌的I/Ib期研究
本研究为I/Ib期3+3设计联合最大耐受剂量扩展研究,纳入52例难治性转移性错配修复功能完整(pMMR)结直肠癌(CRC)患者,评估瑞戈非尼联合纳武利尤单抗的安全性与疗效。最大耐受剂量为瑞戈非尼80 mg联合纳武利尤单抗240 mg每2周一次;3例出现剂量限制性毒性(均为3级皮疹);40例可评估患者中4例(10%)达部分缓解,疾病控制率63%,中位无进展生存期4.3个月,中位总生存期11.1个月。结论认为该方案耐受性良好但抗肿瘤活性有限。
要点
- 最大耐受剂量为瑞戈非尼80 mg联合纳武利尤单抗240 mg每2周一次。
- 40例可评估患者中4例(10%)达部分缓解,疾病控制率63%。
- 中位无进展生存期4.3个月,中位总生存期11.1个月。
核心结论
- 瑞戈非尼联合纳武利尤单抗在转移性pMMR结直肠癌中似乎耐受性良好,但抗肿瘤活性有限。
研究设计与样本
- 本研究为I/Ib期研究,采用标准3+3设计并在最大耐受剂量(MTD)下进行剂量扩展。
- 共纳入52例难治性转移性pMMR结直肠癌患者,其中51例至少接受一剂治疗。
- 主要终点为剂量限制性毒性(DLT)和MTD,次要终点为客观缓解率、安全性和总生存期(OS)。
- 患者接受瑞戈非尼联合纳武利尤单抗治疗。
主要发现
- 3例患者发生DLT,均为3级皮疹。
- 最常见的3/4级治疗相关不良事件为高血压(16%)、皮疹(10%)和贫血(6%)。
- 40例可评估患者中,4例(10%)达部分缓解(其中1例为未确认缓解),21例(53%)达疾病稳定,疾病控制率为63%。
- 中位无进展生存期为4.3个月,中位总生存期为11.1个月。
关键数值与推荐
- MTD为瑞戈非尼80 mg联合纳武利尤单抗240 mg每2周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: In contrast to mismatch repair deficient (dMMR) colorectal cancer (CRC), mismatch repair proficient (pMMR) CRC is usually unresponsive to anti-PD-1 immunotherapy. Recent preclinical data suggest that regorafenib may enhance the antitumor activity of anti-PD-1 immunotherapy. However, the safety and efficacy of regorafenib plus nivolumab have not been established in patients with refractory metastatic pMMR CRC. This study aimed to evaluate the safety and efficacy of regorafenib plus nivolumab in metastatic pMMR metastatic CRC. METHOD: This was a phase I/Ib study with standard 3 + 3 design plus dose expansion of the maximum tolerated dose (MTD) in patients with refractory metastatic pMMR CRC. Patients were treated with regorafenib combined with nivolumab. The primary end-points were dose-limiting toxicity (DLT) and MTD. The secondary end-points were objective response rate, safety and overall survival (OS). RESULTS: A total of 52 patients were enrolled, and 51 patients received at least one dose of treatment. Three patients experienced DLT (all grade 3 rash). MTD was regorafenib 80 mg and nivolumab 240 mg every 2 weeks. Most common grade 3/4 treatment-related adverse events were hypertension (16%), rash (10%) and anaemia (6%). Among 40 evaluable patients, four (10%) achieved partial response, including one unconfirmed response, 21 (53%) achieved stable disease, and disease control rate was 63%. The median progression-free survival and OS were 4.3 and 11.1 months, respectively. CONCLUSIONS: Regorafenib plus nivolumab appears to be well tolerated with limited anticancer activity in metastatic pMMR CRC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03712943.
引用
- Kim RD, Kovari BP, Martinez M, et al. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022. PMID: 35526308. doi:10.1016/j.ejca.2022.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。